Tulisokibart demonstrated efficacy in a Phase 2b study enrolling patients with moderate to severe hidradenitis suppurativa (HS), according to data reported by HCPLive — an early-stage but clinically meaningful signal in a disease where treatment options remain limited.

The trial population — moderate to severe HS — is the cohort dermatologists know best from the registrational programs of currently approved biologics. In this population, endpoints such as HiSCR50 and HiSCR75 (a 50% or 75% reduction in abscesses and inflammatory nodules with no increase in draining fistulae or abscesses) are the standard efficacy bar. Tulisokibart now joins the list of investigational agents that have cleared that bar at the Phase 2b stage.

Why a Phase 2b HS readout matters

HS therapeutics remain crowded at the top by only a handful of approved agents, and real-world response is often partial or wanes over time. Dermatologists managing Hurley stage II and III disease routinely cycle patients through approved biologics and off-label options, so any new mechanism with Phase 2b evidence draws immediate interest.

The moderate-to-severe designation places the study squarely in the population where regulatory pathways for HS are typically built. A Phase 2b efficacy signal in this cohort generally supports progression to pivotal Phase 3 testing, where durability of response, safety over longer exposure and dosing convenience become the deciding questions.

What tulisokibart brings to the pipeline

For pipeline watchers, the significance of this readout is straightforward: another investigational candidate has generated positive efficacy data in HS at the Phase 2b stage. Whether tulisokibart differentiates itself on magnitude of response, flare reduction, fistular disease or safety profile will depend on fuller datasets and head-to-head-adjacent comparisons that Phase 2b programs rarely provide.

Questions dermatologists will ask as data mature:

• What proportion of patients achieved HiSCR50 and HiSCR75?
• How durable was the response across the dosing interval?
• Did patients with draining fistulae — typically the hardest-to-treat subset — benefit?
• What was the safety and tolerability profile relative to approved agents?

The competitive backdrop

HS drug development has intensified as the unmet need in Hurley stage III disease, pain burden and quality-of-life impairment has become better quantified. Multiple sponsors now hold HS assets across phases, and Phase 2b results such as these function as proof-of-concept currency: they justify continued investment and shape where the candidate sits in the treatment algorithm if it eventually reaches approval.

For clinicians, the practical takeaway is measured. No practice change follows a Phase 2b result. What it does signal is that the HS pipeline continues to broaden beyond currently marketed mechanisms, raising the likelihood that patients who fail or respond incompletely to existing therapy will have additional options within the typical drug-development horizon.

What comes next

The reported Phase 2b efficacy establishes tulisokibart as a credible HS pipeline candidate; the field will now watch for detailed response rates, safety tables and any announcement of a Phase 3 program.